Hong, Fang-Tsao et al. published their research in Journal of Medicinal Chemistry in 2014 | CAS: 936902-12-4

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (cas: 936902-12-4) belongs to benzoxazole derivatives. Its aromaticity makes it relatively stable, although as a heterocycle, it has reactive sites which allow for functionalization. In the past years, numerous benzoxazole derivatives have been synthesised and evaluated for their biological potential.Product Details of 936902-12-4

Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 4. Exploration of a Novel Binding Pocket was written by Hong, Fang-Tsao;Norman, Mark H.;Ashton, Kate S.;Bartberger, Michael D.;Chen, Jie;Chmait, Samer;Cupples, Rod;Fotsch, Christopher;Jordan, Steven R.;Lloyd, David J.;Sivits, Glenn;Tadesse, Seifu;Hale, Clarence;St. Jean, David J. Jr.. And the article was included in Journal of Medicinal Chemistry in 2014.Product Details of 936902-12-4 This article mentions the following:

Structure-activity relationship investigations conducted at the 5-position of the N-pyridine ring of a series of N-arylsulfonyl-N’-2-pyridinyl-piperazines led to the identification of a novel bis-pyridinyl piperazine sulfonamide I that was a potent disruptor of the glucokinase-glucokinase regulatory protein (GK-GKRP) interaction. Anal. of the x-ray cocrystal of compound I bound to hGKRP revealed that the 3-pyridine ring moiety occupied a previously unexplored binding pocket within the protein. Key features of this new binding mode included forming favorable contacts with the top face of the Ala27-Val28-Pro29 (“shelf region”) as well as an edge-to-face interaction with the Tyr24 side chain. Compound I was potent in both biochem. and cellular assays (IC50 = 0.005 μM and EC50 = 0.205 μM, resp.) and exhibited acceptable pharmacokinetic properties for in vivo evaluation. When administered to db/db mice (100 mg/kg, po), compound I demonstrated a robust pharmacodynamic effect and significantly reduced blood glucose levels up to 6 h postdose. In the experiment, the researchers used many compounds, for example, 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (cas: 936902-12-4Product Details of 936902-12-4).

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole (cas: 936902-12-4) belongs to benzoxazole derivatives. Its aromaticity makes it relatively stable, although as a heterocycle, it has reactive sites which allow for functionalization. In the past years, numerous benzoxazole derivatives have been synthesised and evaluated for their biological potential.Product Details of 936902-12-4

Referemce:
Benzoxazole – Wikipedia,
Benzoxazole | C7H5NO – PubChem